Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.23 · Revenue $72.66M · 6 analysts
Est. EPS $-0.10 · Revenue $93.82M · 5 analysts
Est. EPS $-0.73 · Revenue $363.12M · 8 analysts
Est. EPS $-0.31 · Revenue $13.47M · 3 analysts
EPS $2.93 · Revenue $666.65M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.1B | +64.7% | -59.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $440.3M | +334.8% | -462.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +93.7% | +33.3% | -4.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +50.1% | +237.4% | -775.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +39.2% | +242.6% | -1284.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-250.2M | -149.4% | -120.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -22.3% | -51.4% | -441.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -194.8% | -427.3% | +24.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.13x | +117.5% | -6.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.2B | -24.6% | -8.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 2.54 vs 2.23 | +13.7% | -0.32 vs -0.38 | +15.8% |
| Revenue Surprise | $1.1B vs $1.1B | +5.6% | $56.7M vs $52.5M | +8.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 20, 2026 | Rodgers Richard J | director | Common Stock | A | 18,880 | — |
| Jun 20, 2026 | Rodgers Richard J | director | Restricted Stock Units | D | 18,880 | — |
| Jun 20, 2026 | King Rachel K. | director | Common Stock | A | 18,880 | — |
| Jun 20, 2026 | King Rachel K. | director | Restricted Stock Units | D | 18,880 | — |
| Jun 20, 2026 | DOUGLAS RICHARD | director | Common Stock | A | 18,880 | — |
James Kelly: Good morning, and thank you for joining us today to discuss our first quarter 2026 financial results and operational highlights. A press release announcing our results is available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today. Please turn to Slide 2. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including, but not limited to, statements related to Novavax's corporate strategy and operating plans, its strategic priorities, its partnerships and expectations with respect to potential royalties, milestones, cost reimbursements, the current macro and regulatory environment, the development of Novavax's clinical and preclinical product candidates, the timing and results of clinical trials, timing of regulatory filings and actions, its APA agreements and related negotiations, projected market opportunity, full year 2026 financial guidance and revenue framework and Novavax's future financial or business performance, including long-term growth, cost savings and profitability targets. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding these factors appears under the heading Cautionary Note regarding forward-looking statements in the presentation we issued this morning and under the heading Risk Factors in our most recent Form 10-K and subsequent Form 10-Qs filed with the Securities and Exchange Commission available at www.sec.gov and on our website at www.novavax.com. The forward-looking statements in this presentation are only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements. Please turn to Slide 3. This presentation also includes references to non-GAAP financial measures, including total adjusted revenue and combined R&D and SG&A expenses, less partner reimbursements and non-GAAP profitability. Please turn to Slide 4. Joining me today is John Jacobs, our President and CEO; Elaine O'Hara, Chief Strategy Officer; and Bob Walker, Head of R&D. Please turn to Slide 5. I would now like to hand the call over to John. John Jacobs: Thank you, Jim. I'm excited to be here today with members of our executive team to share our first quarter 2026 financial results and operational highlights. Novavax ended the first quarter having made significant progress against our top priorities and growth strategy, which is designed to deliver value via 3 key strategic pillars, partnering our technology, capital-efficient R&D innovation and a lean and efficient operating model supporting our efforts. Please turn to Slide 6. Our ambition is clear, to build the future Novavax with multiple partners, both large global pharmaceutical companies and smaller, highly innovative …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
John Charles Jacobs | President, Chief Executive Officer & Director | USD 1,547,288 | Male | 1967 | Active |
Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary | USD 984,255 | Male | 1963 | Active |
Elaine O'Hara | Executive Vice President & Chief Strategy Officer | USD 947,011 | Female | 1968 | Active |
James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | USD 884,281 | Male | 1966 | Active |
Naina Zaman | Director of Investor Relations | — | Female | — | Active |
Richard Crowley | Executive Vice President & Chief Operating Officer | — | Male | 1957 | Active |
Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | — | Male | 1971 | Active |
Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | — | Male | 1963 | Active |
Luis Sanay | Vice President of Investor Relations | — | — | — | Active |
Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | — | Female | — | Active |
Erika S. Trahan | Associate Director of Investor & Public Relations | — | Female | — | Active |
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid⢠Approvals in the U.S., EU and Japan for 2026-2027 Vaccination
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan.
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG variant.
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
A third drug stock making plenty of progress in today's trading
